|
|
|
|
|
|
by winocm
1714 days ago
|
|
|
If you saw any form of antibody-dependent enhancement, signals would be far spread now, considering how much viral spread is occurring... > However, using monkey and mouse models of SARS-CoV-2 infection, none of the in vitro infection-enhancing Abs enhanced SARS-CoV-2 virus replication or infectious virus in the lung in vivo. Three of 46 monkeys had lung pathology or bronchoalveolar lavage (BAL) cytokine levels greater than controls. However, repeat studies with dose ranges of in vitro enhancing Abs did not increase lung pathology. Thus, in vitro infection-enhancing RBD and NTD Abs controlled virus in vivo and was rarely associated with enhanced lung pathology. [1] 1: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232969/ |
|
|